Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > New Patent + Advancing New DPEP-1 Drugs = Phase II Results

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Oct 01, 2021 10:09am

86 Views

Post# 33951761

RE:New Patent + Advancing New DPEP-1 Drugs = Phase II Results

Everyone has the eye on the PHASE II results but look at the progress the company is making at advancing the new Mechanism of Action with additional grants and patents. During the webinar i recall the CSO mentioning 8 drugs but my memory could be foggy. These third party results could prove out the whole drug library.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages